Cargando…
Gene Therapy Progress and Prospects: Cystic fibrosis
Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer age...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091818/ https://www.ncbi.nlm.nih.gov/pubmed/12364999 http://dx.doi.org/10.1038/sj.gt.3301791 |
_version_ | 1783510065919033344 |
---|---|
author | Griesenbach, U Ferrari, S Geddes, D M Alton, E W F W |
author_facet | Griesenbach, U Ferrari, S Geddes, D M Alton, E W F W |
author_sort | Griesenbach, U |
collection | PubMed |
description | Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer agents (adenovirus (Ad), adeno-associated virus 2 (AAV2) and cationic liposomes) was low, and most likely insufficient to achieve clinical benefit. Here, we will review the clinical and pre-clinical progress for the last 2 years (2000–2001) and briefly speculate on future prospects for the next 2 in CF gene therapy. |
format | Online Article Text |
id | pubmed-7091818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70918182020-03-24 Gene Therapy Progress and Prospects: Cystic fibrosis Griesenbach, U Ferrari, S Geddes, D M Alton, E W F W Gene Ther Article Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer agents (adenovirus (Ad), adeno-associated virus 2 (AAV2) and cationic liposomes) was low, and most likely insufficient to achieve clinical benefit. Here, we will review the clinical and pre-clinical progress for the last 2 years (2000–2001) and briefly speculate on future prospects for the next 2 in CF gene therapy. Nature Publishing Group UK 2002-10-03 2002 /pmc/articles/PMC7091818/ /pubmed/12364999 http://dx.doi.org/10.1038/sj.gt.3301791 Text en © Macmillan Publishers Limited 2002 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Griesenbach, U Ferrari, S Geddes, D M Alton, E W F W Gene Therapy Progress and Prospects: Cystic fibrosis |
title | Gene Therapy Progress and Prospects: Cystic fibrosis |
title_full | Gene Therapy Progress and Prospects: Cystic fibrosis |
title_fullStr | Gene Therapy Progress and Prospects: Cystic fibrosis |
title_full_unstemmed | Gene Therapy Progress and Prospects: Cystic fibrosis |
title_short | Gene Therapy Progress and Prospects: Cystic fibrosis |
title_sort | gene therapy progress and prospects: cystic fibrosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091818/ https://www.ncbi.nlm.nih.gov/pubmed/12364999 http://dx.doi.org/10.1038/sj.gt.3301791 |
work_keys_str_mv | AT griesenbachu genetherapyprogressandprospectscysticfibrosis AT ferraris genetherapyprogressandprospectscysticfibrosis AT geddesdm genetherapyprogressandprospectscysticfibrosis AT altonewfw genetherapyprogressandprospectscysticfibrosis |